A meta-analysis compared the incidence of CIP among different therapeutic regimens in melanoma, and the result showed that combination therapy had a higher incidence of CIP than PD-1 inhibitor monotherapy for all grades (6.6% vs. 1.6%) and grade 3 or higher (1.5% vs. 0.2%) (6). This evidence concerns the gene PDCD1 and melanoma.